| Cat. No. |
Product Name |
Information |
| PC-21081 |
Allopole
PLK1 PBD inhibitor
|
Allopole is the first allosteric, specfic and cell-permeable inhibitor of the noncatalytic polo-box domain (PBD) of PLK1 (Polo-like kinase 1), Allopole is the prodrug of Allopole-A. |
| PC-21080 |
Allopole-A
PLK1 PBD inhibitor
|
Allopole-A is the first allosteric, specfic inhibitor of the noncatalytic polo-box domain (PBD) of PLK1 (Polo-like kinase 1) with IC50 of 2.5 nM in FP-based assays, Allopole-A is the active form of Allopole. |
| PC-20477 |
MCC1019
PLK1 PBD inhibitor
|
MCC1019 is a selective inhibitor of PLK1, targets PLK1 Polo box domain (PBD) with binding IC50 of 16.4 uM, 2.75-fold over PLK2-PBD (IC50=44.1 uM) and > 6-fold higher specificity over PLK3 PBD (IC50 >100 uM). |
| PC-73207 |
ON1231320
PLK2 inhibitor
|
ON1231320 is a highly specific, ATP-mimetic polo-like kinase 2 (PLK2) inhibitor with IC50 of 0.31 uM. |
| PC-35728 |
YLT-11
PLK4 inhibitor
|
YLT-11 (PLK4 inhibitor YLT11) is a novel potent, selective, ATP-competitive PLK4 inhibitor with IC50 of 22 nM, Kd of 5.2 nM. |
| PC-63238 |
CFI-400945 fumarate
PLK4 inhibitor
|
CFI-400945 (Ocifisertib) fumarate is a potent, highly selective, orally available PLK4 inhibitor with Ki of 0.26 nM and IC50 of 2.8 nM, does not significantly inhibits PLK1/2/3 at 50 uM. |
| PC-42963 |
CFI-400945
PLK4 inhibitor
|
CFI-400945 is a potent, highly selective PLK4 inhibitor with Ki of 0.26 nM and IC50 of 2.8 nM, does not significantly inhibits PLK1/2/3 at 50 uM. |
| PC-42899 |
Volasertib
PLK inhibitor
|
Volasertib (BI 6727) is a potent, selective Polo-like kinase (PLK) inhibitor with IC50 of 0.87, 5 and 56 nM for PLK1, 2 and 3, respectively. |
| PC-42860 |
HMN-214
PLK1 inhibitor
|
HMN-214 (IVX 214, TV-7101) is a prodrug of HMN-176 for oral administration, HMN-176 is a stilbene derivative that interferes with the subcellular spatial location of PLK1, does not inhibit PLK directly. |
| PC-42852 |
Rigosertib
PLK1 inhibitor
|
Rigosertib (ON 01910) is a potent, non-ATP-competitive PLK1 inhibitor (IC50=9-10 nM), selectively induces mitotic G2/M arrest and apoptosis in cancer cells. |
| PC-42851 |
Rigosertib sodium
PLK1 inhibitor
|
Rigosertib sodium (ON 01910.Na) is a potent, non-ATP-competitive PLK1 inhibitor (IC50=9-10 nM), selectively induces mitotic G2/M arrest and apoptosis in cancer cells. |
| PC-63063 |
T-521
PLK1 inhibitor
|
T-521 is a novel PLK1 PBD (Polo-box domain) inhibitor that specifically inhibits the PBD of PLK1 (IC50=1.22 uM), but not those of Plk2-3. |
